A Study of Vagus Nerve Blocking for Obesity Control

Overview

Información sobre este estudio

The purpose of this study is to measure the safety and effectiveness of the Maestro System to reduce body weight by blocking signals from the vagus nerve in people who are considered to be obese.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Informed consent
  • Body mass index (BMI) ≥ 40 kg/m2 to 45 kg/m2 
  • BMI ≥ 35 kg/m2 to 39.9 kg/m2 with one or more severe obesity related co-morbid conditions
  • Female or male
  • Age 18-65 years inclusive
  • Type 2 diabetes mellitus that is well-controlled
    • At selected centers
    • Limited to approximately 26 subjects
  • Failed to respond to a supervised diet/exercise program engaged in for at least 6 months
  • Able to complete all study visits and procedures

Exclusion Criteria

  • Concurrent chronic pancreatic disease
  • History of Crohn's disease and/or ulcerative colitis
  • History of bariatric surgery, fundoplication, gastric resection or major upper-abdominal surgery
  • History of pulmonary embolism or blood coagulation disorders
  • Clinically significant hiatal hernia known from medical record or determined by upper endoscopy prior to implant
  • Current portal hypertension and/or esophageal varices
  • Intra-operative exclusion for hiatal hernia requiring surgical repair or extensive dissection at esophagogastric junction at the time of surgery
  • Treatment with weight-loss prescription drug therapy within the prior three months, and the use of prescription drug therapy or over-the-counter weight loss preparations for the duration of the trial
  • Smoking cessation within the prior six months
  • Known genetic cause of obesity
  • Overall sustained reduction of more than 10% of body weight in the previous 12 months
  • Pre-operative diet with intent to lose weight prior to surgery

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Florencia Que, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20315807

Mayo Clinic Footer